JP7385561B2 - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP7385561B2
JP7385561B2 JP2020520592A JP2020520592A JP7385561B2 JP 7385561 B2 JP7385561 B2 JP 7385561B2 JP 2020520592 A JP2020520592 A JP 2020520592A JP 2020520592 A JP2020520592 A JP 2020520592A JP 7385561 B2 JP7385561 B2 JP 7385561B2
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536924A5 (https=
JP2020536924A (ja
Inventor
マレ，リチャード
スプリンガー，キャロライン
ニクレスク－デュヴァツ，ダン
ミラー，ナタリー
アルジャラー，モハメッド
ザンボン，アルフォンソ
リャン，レオ
スミスン，デボラ
ブラウン，ミカエル
タン，ハオラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Publication of JP2020536924A publication Critical patent/JP2020536924A/ja
Publication of JP2020536924A5 publication Critical patent/JP2020536924A5/ja
Application granted granted Critical
Publication of JP7385561B2 publication Critical patent/JP7385561B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020520592A 2017-10-13 2018-10-12 化合物 Active JP7385561B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1716871.7A GB201716871D0 (en) 2017-10-13 2017-10-13 Compounds
GB1716871.7 2017-10-13
PCT/GB2018/052934 WO2019073251A1 (en) 2017-10-13 2018-10-12 INHIBITORS OF LYSYL OXIDASE

Publications (3)

Publication Number Publication Date
JP2020536924A JP2020536924A (ja) 2020-12-17
JP2020536924A5 JP2020536924A5 (https=) 2021-11-11
JP7385561B2 true JP7385561B2 (ja) 2023-11-22

Family

ID=60419229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520592A Active JP7385561B2 (ja) 2017-10-13 2018-10-12 化合物

Country Status (8)

Country Link
US (2) US11325915B2 (https=)
EP (1) EP3694857A1 (https=)
JP (1) JP7385561B2 (https=)
CN (1) CN111212836B (https=)
CA (1) CA3076566A1 (https=)
GB (1) GB201716871D0 (https=)
IL (1) IL273727B2 (https=)
WO (1) WO2019073251A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN112533897B (zh) 2018-08-03 2023-07-14 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺砜衍生抑制剂及其用途
GB201818750D0 (en) * 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
AU2020317374A1 (en) * 2019-07-25 2022-02-03 Pharmaxis Ltd. Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US12578335B2 (en) 2020-02-05 2026-03-17 Syntara Limited Bioprobes for lysyl oxidases and uses thereof
US20230310445A1 (en) * 2020-04-21 2023-10-05 Anovia Biosciences, Inc. Lox enzyme inhibiting methods and compositions
US12233056B2 (en) 2022-04-06 2025-02-25 Syntara Limited Lysyl oxidase inhibitors for treating myeloid malignancies
CN116763899B (zh) * 2023-07-17 2026-02-24 大连医科大学附属第一医院 Htra1抑制剂在制备治疗胰腺炎-癌转化的药物中的应用
CN119732928B (zh) * 2024-12-26 2026-04-07 国家纳米科学中心 一种抑制胶原纤维形成的药物分子及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543785A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
JP2011507824A (ja) 2007-12-21 2011-03-10 アストラゼネカ アクチボラグ アンドロゲン受容体関連状態の治療に使用の二環系誘導体
WO2016085783A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
JP2016537368A (ja) 2013-11-14 2016-12-01 ノヴィラ・セラピューティクス・インコーポレイテッド アゼパン誘導体及びｂ型肝炎感染の治療方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992546A (en) 1987-07-31 1991-02-12 Warner-Lambert Company Process for preparing 6,8-diazabicyclo[3.2.2]nonane derivatives
DE4402933A1 (de) 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2011119345A2 (en) 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3267996B1 (en) * 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
EP3317258A4 (en) * 2015-07-01 2019-06-26 Pharmakea, Inc. LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF
ES2880766T3 (es) 2016-02-09 2021-11-25 Pharmakea Inc Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
JP6849197B2 (ja) 2016-02-12 2021-03-24 ファーマクシス リミテッド リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
US20210009551A1 (en) 2016-06-02 2021-01-14 The Regents Of The University Of California Compounds and methods for treating fibrosis or cancer
WO2018048928A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Chemical probes of lysyl oxidase-like 2 and uses thereof
WO2018048930A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
KR102587178B1 (ko) 2016-09-07 2023-10-06 파마케아, 인크. 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법
US20200069648A1 (en) 2017-03-02 2020-03-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543785A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
JP2011507824A (ja) 2007-12-21 2011-03-10 アストラゼネカ アクチボラグ アンドロゲン受容体関連状態の治療に使用の二環系誘導体
JP2016537368A (ja) 2013-11-14 2016-12-01 ノヴィラ・セラピューティクス・インコーポレイテッド アゼパン誘導体及びｂ型肝炎感染の治療方法
WO2016085783A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry，2012年，20(5)，P.1671-1678

Also Published As

Publication number Publication date
CN111212836B (zh) 2023-12-15
US20200331922A1 (en) 2020-10-22
EP3694857A1 (en) 2020-08-19
GB201716871D0 (en) 2017-11-29
US12060360B2 (en) 2024-08-13
US11325915B2 (en) 2022-05-10
CA3076566A1 (en) 2019-04-18
US20220289757A1 (en) 2022-09-15
WO2019073251A1 (en) 2019-04-18
JP2020536924A (ja) 2020-12-17
IL273727B2 (en) 2023-06-01
CN111212836A (zh) 2020-05-29
IL273727A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
JP7385561B2 (ja) 化合物
CN114867726A (zh) Kras g12c突变体的小分子抑制剂
JP2025037925A (ja) 協同的結合に関与する化合物及びその使用
JP7601762B2 (ja) Ｌｏｘ阻害剤
CN117715658A (zh) 抑制ras的方法
CN120112518A (zh) 用于治疗癌症的化合物
JP7437322B2 (ja) ＬＯＸ阻害剤として有用なヘキサヒドロピロロ［３，４－ｃ］ピロール誘導体
JP2022507559A (ja) Ａｍ２受容体阻害剤としての複素環スピロ化合物
JP2022507561A (ja) Ａｍ２受容体阻害剤としての複素環スピロ化合物
JP7808616B2 (ja) 環式化合物及びそれを使用する方法
TWI917313B (zh) 參與協同結合之化合物及其用途
HK40127987A (en) Cyclic compounds and methods of using same
CN120359224A (zh) 取代的杂环化合物衍生物及其制药用途
EA047571B1 (ru) Низкомолекулярные ингибиторы g12c-мутантного kras

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7385561

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150